I precept and teach medical students, residents and fellows in the field of clinical hematology and medical oncology, with a focus on diagnosis, work up and clinical management, preferring clinical trials. I have a special interest in the field of lung cancer and head and neck cancer, especially in multimodality therapy combining radiation with chemotherapy and immunotherapy.
Early-Stage Lung Adenocarcinoma treated with Stereotactic Body Radiation Therapy (SBRT)
Lung Cancer: Lung Cancer Regional Snapshot Kansas City VA Medical Center
- Modulation of microRNA expression in EGFR-tyrosine kinase inhibitor-resistant non-small cell lung cancer cell lines. Proceedings of the American Association for Cancer Research Y Volume 59 Y April 2018
Patient-Defined Treatment Success: Perspectives of Patients With Advanced-Stage Lung Cancer
Positivity Rates in Oropharyngeal and Nonoropharyngeal Head and Neck Cancer in the VA
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer
Randomized Phase 2 Study of Tivantinib Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer
A Phase 3, Controlled, Open-label Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Carcinoma
A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma
A Randomized Phase II Trial of Trimodality Therapy +/- Immunotherapy in Resectable Superior Sulcus Non-Small Cell Lung Cancer
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
S1800A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) versues Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (lung-MAP Non-matched Sub-Study)